New brain degenerative drugs will undergo more detailed clinical trials November 08, 2016 Source: Drug Information Network The compound, called Verubecestat, reduces amyloid deposition by blocking an enzyme called BACE1. For patients with dementia, protein-forming plaques can damage the brain, especially affecting cognitive abilities such as memory, while BACE1 plays an important role in plaque formation.
Carbomer is an acrylic resin obtained by cross-linking pentaerythritol with acrylic acid. It is a very important rheological regulator. After neutralization, carbomer is an excellent gel matrix, which has important applications such as thickening suspension. According to the dry product calculation, including carboxylic acid group (-cooh) should be 56.0 % ~ 68.0%.
Common carbopol series include: Carbopol 940, 941, 934, 1342, 980, ETD 2020, AQUA sf-1, Ultrez 21, Ultrez 20, etc.
Carbomer,Carbopol,Carbopol 940, Carbomer 940, Carbomer 980, acrylic acid Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualynbio.com
Â
At present, many pharmaceutical companies are committed to the development of drugs that can prevent or even reverse the formation of these spots, but most of the drugs will have large side effects, resulting in liver damage or further neurodegenerative diseases. In 32 patients who participated in this first phase clinical trial and suffered from mild to moderate dementia , protein deposition decreased after taking one to two doses of this new drug for dementia , and no side effects were found.